Effect of lanthanum carbonate versus calciumbased phosphate binders in dialysis patients: a meta-analysis
| Autor: | Qiao-Ling Sun, Chun-Juan Zhai, Lin Li, Li-Ting Zhang, Rong Wang, Xin-Shuang Yu, Ai-Yan Zhou |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
business.industry Incidence (epidemiology) Significant difference chemistry.chemical_element General Medicine Calcium Phosphate Dialysis patients Gastroenterology law.invention chemistry.chemical_compound Lanthanum carbonate chemistry Randomized controlled trial Nephrology law Meta-analysis Internal medicine medicine business medicine.drug |
| Zdroj: | Clinical Nephrology. 82:372-378 |
| ISSN: | 0301-0430 |
| DOI: | 10.5414/cn108361 |
| Popis: | Background The effects of lanthanum carbonate (LC) vs. calciumbased phosphate binders in dialysis patients have been a matter of debate. Methods We electronically searched PubMed, Embase, CENTRAL, and CBM for all randomized controlled trials comparing LC with calcium-based phosphate binders in adult dialysis patients. Quality assessment was performed using the Cochrane risk of bias tool. Metaanalysis was conducted by RevMan 5.2. Results Nine studies were eligible for our meta-analysis. There was no significant difference in all-cause mortality (RR 0.84, 95% CI 0.25 - 2.83) and cardiovascular events (RR 0.84, 95% CI 0.55 - 1.29) between LC and calcium-based phosphate binders. LC was associated with similar proportions of phosphate-controlled patients (RR 0.63, 95% CI 0.27 - 1.44) and lower incidence of hypercalcemia (RR 0.13, 95% CI 0.05 - 0.35) in comparison to calcium-based phosphate binders. Compared with calcium salts, LC was associated with significantly lower serum calcium, similar serum Ca x P product and higher serum iPTH. Conclusion Despite the trends observed, we found no statistically significant differences in all-cause mortality and cardiovascular events between LC and calcium-based phosphate binders in dialysis patients. The conclusion was limited by lack of large sample and long-term trials. LC could reduce the incidence of hypercalcemia while comparable with calcium-based phosphate binders in reducing serum phosphorus level. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|